Merck 8-K 2007
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Merck & Co., Inc.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)(c) Effective August 14, 2007, the Board of Directors of Merck & Co., Inc. ("Merck" or the "Company") approved the election of Peter N. Kellogg to the office of Executive Vice President and Chief Financial Officer, making him the Company's principal financial officer. Judy C. Lewent, Merck’s current Executive Vice President and Chief Financial Officer, who is retiring, has resigned that position effective the same date.
Item 9.01 Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.